Longitudinal Changes of Circulating miRNAs During Bisphosphonate and Teriparatide Treatment in an Animal Model of Postmenopausal Osteoporosis.

Weigl M, Kocijan R, Ferguson J, Leinfellner G, Heimel P, Feichtinger X, Pietschmann P, Grillari J, Zwerina J, Redl H, Hackl M

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research10 Mar 2021Cited by 24 (Europe PMC)

PMID33598975PMCIDPMC8252367DOI10.1002/jbmr.4276PepBankPUB-33598975

Read at source PubMedAsk about this study

Jump to 14 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study14

11 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In ovariectomized rats, teriparatide reversed trabecular bone loss.
In plain wordsIn rats with ovaries removed, teriparatide reversed spongy bone loss compared with vehicle treatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseTrabecular bone loss
Study
Sprague Dawley ratsn: not reported in source
Ovariectomized rats
Comparator
Vehicle-treated ovariectomized rats
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 12 weeksAs given in this study (Sprague Dawley rats).
Source sentences
Summary
Ovariectomy resulted in the loss of trabecular bone, which was reversed by osteoanabolic and antiresorptive treatment.
2 context sentences(design, population, supporting numbers)
Summary · context
Therefore, we performed a comprehensive analysis of microRNA serum levels in ovariectomized (OVX) and sham-operated (SHAM) rats over 12 weeks of antiresorptive or osteoanabolic treatment.
Summary · context
After 8 weeks, OVX rats were randomized to antiresorptive treatment with zoledronate (n = 11), osteoanabolic treatment with teriparatide (n = 11), or vehicle treatment (n = 10).
Report a problemFND-3359897501
02AnimalAnimal study (in vivo)Mechanism
In ovariectomized rats, serum miR-107 decreased during teriparatide treatment but increased with vehicle.
In plain wordsIn rats with ovaries removed, serum miR-107 decreased with teriparatide but increased with vehicle.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseSerum miR-107
Study
Sprague Dawley ratsn: not reported in source
Ovariectomized rats
Comparator
Vehicle-treated ovariectomized rats
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 12 weeksAs given in this study (Sprague Dawley rats).
Source sentences
Summary
For example, miR-107 and miR-31-5p increased in vehicle-treated OVX animals, whereas they decreased during teriparatide treatment.
2 context sentences(design, population, supporting numbers)
Summary · context
Therefore, we performed a comprehensive analysis of microRNA serum levels in ovariectomized (OVX) and sham-operated (SHAM) rats over 12 weeks of antiresorptive or osteoanabolic treatment.
Summary · context
After 8 weeks, OVX rats were randomized to antiresorptive treatment with zoledronate (n = 11), osteoanabolic treatment with teriparatide (n = 11), or vehicle treatment (n = 10).
Report a problemFND-3359897502
03AnimalAnimal study (in vivo)Mechanism
In ovariectomized rats, serum miR-31-5p decreased during teriparatide treatment but increased with vehicle.
In plain wordsIn rats with ovaries removed, serum miR-31-5p decreased with teriparatide but increased with vehicle.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseSerum miR-31-5p
Study
Sprague Dawley ratsn: not reported in source
Ovariectomized rats
Comparator
Vehicle-treated ovariectomized rats
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 12 weeksAs given in this study (Sprague Dawley rats).
Source sentences
Summary
For example, miR-107 and miR-31-5p increased in vehicle-treated OVX animals, whereas they decreased during teriparatide treatment.
2 context sentences(design, population, supporting numbers)
Summary · context
Therefore, we performed a comprehensive analysis of microRNA serum levels in ovariectomized (OVX) and sham-operated (SHAM) rats over 12 weeks of antiresorptive or osteoanabolic treatment.
Summary · context
After 8 weeks, OVX rats were randomized to antiresorptive treatment with zoledronate (n = 11), osteoanabolic treatment with teriparatide (n = 11), or vehicle treatment (n = 10).
Report a problemFND-3359897503
04AnimalAnimal study (in vivo)Mechanism
In ovariectomized rats, teriparatide prevented significant serum miR-34a-5p changes over time seen without treatment.
In plain wordsIn rats with ovaries removed, teriparatide prevented serum miR-34a-5p changes seen without treatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeSerum miR-34a-5p changes
Study
Sprague Dawley ratsn: not reported in source
Ovariectomized rats
Comparator
Vehicle-treated ovariectomized rats
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 12 weeksAs given in this study (Sprague Dawley rats).
Source sentences
Summary
Longitudinal analysis confirmed eight microRNAs with significant changes in serum over time that were prevented by teriparatide and zoledronate treatment (miR-34a-5p, miR-31-5p, miR-30d-3p, miR-378a-5p) or teriparatide treatment only (miR-375-3p, miR-183-5p, miR-203a-3p, miR-203b-3p).
2 context sentences(design, population, supporting numbers)
Summary · context
Therefore, we performed a comprehensive analysis of microRNA serum levels in ovariectomized (OVX) and sham-operated (SHAM) rats over 12 weeks of antiresorptive or osteoanabolic treatment.
Summary · context
After 8 weeks, OVX rats were randomized to antiresorptive treatment with zoledronate (n = 11), osteoanabolic treatment with teriparatide (n = 11), or vehicle treatment (n = 10).
Report a problemFND-3359897504
05AnimalAnimal study (in vivo)Mechanism
In ovariectomized rats, teriparatide prevented significant serum miR-31-5p changes over time seen without treatment.
In plain wordsIn rats with ovaries removed, teriparatide prevented serum miR-31-5p changes seen without treatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeSerum miR-31-5p changes over time
Study
Sprague Dawley ratsn: not reported in source
Ovariectomized rats
Comparator
Vehicle-treated ovariectomized rats
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 12 weeksAs given in this study (Sprague Dawley rats).
Source sentences
Summary
Longitudinal analysis confirmed eight microRNAs with significant changes in serum over time that were prevented by teriparatide and zoledronate treatment (miR-34a-5p, miR-31-5p, miR-30d-3p, miR-378a-5p) or teriparatide treatment only (miR-375-3p, miR-183-5p, miR-203a-3p, miR-203b-3p).
2 context sentences(design, population, supporting numbers)
Summary · context
Therefore, we performed a comprehensive analysis of microRNA serum levels in ovariectomized (OVX) and sham-operated (SHAM) rats over 12 weeks of antiresorptive or osteoanabolic treatment.
Summary · context
After 8 weeks, OVX rats were randomized to antiresorptive treatment with zoledronate (n = 11), osteoanabolic treatment with teriparatide (n = 11), or vehicle treatment (n = 10).
Report a problemFND-3359897505
06AnimalAnimal study (in vivo)Mechanism
In ovariectomized rats, teriparatide prevented significant serum miR-30d-3p changes over time seen without treatment.
In plain wordsIn rats with ovaries removed, teriparatide prevented serum miR-30d-3p changes seen without treatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeSerum miR-30d-3p changes
Study
Sprague Dawley ratsn: not reported in source
Ovariectomized rats
Comparator
Vehicle-treated ovariectomized rats
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 12 weeksAs given in this study (Sprague Dawley rats).
Source sentences
Summary
Longitudinal analysis confirmed eight microRNAs with significant changes in serum over time that were prevented by teriparatide and zoledronate treatment (miR-34a-5p, miR-31-5p, miR-30d-3p, miR-378a-5p) or teriparatide treatment only (miR-375-3p, miR-183-5p, miR-203a-3p, miR-203b-3p).
2 context sentences(design, population, supporting numbers)
Summary · context
Therefore, we performed a comprehensive analysis of microRNA serum levels in ovariectomized (OVX) and sham-operated (SHAM) rats over 12 weeks of antiresorptive or osteoanabolic treatment.
Summary · context
After 8 weeks, OVX rats were randomized to antiresorptive treatment with zoledronate (n = 11), osteoanabolic treatment with teriparatide (n = 11), or vehicle treatment (n = 10).
Report a problemFND-3359897506
07AnimalAnimal study (in vivo)Mechanism
In ovariectomized rats, teriparatide prevented significant serum miR-378a-5p changes over time seen without treatment.
In plain wordsIn rats with ovaries removed, teriparatide prevented serum miR-378a-5p changes seen without treatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeSerum miR-378a-5p changes
Study
Sprague Dawley ratsn: not reported in source
Ovariectomized rats
Comparator
Vehicle-treated ovariectomized rats
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 12 weeksAs given in this study (Sprague Dawley rats).
Source sentences
Summary
Longitudinal analysis confirmed eight microRNAs with significant changes in serum over time that were prevented by teriparatide and zoledronate treatment (miR-34a-5p, miR-31-5p, miR-30d-3p, miR-378a-5p) or teriparatide treatment only (miR-375-3p, miR-183-5p, miR-203a-3p, miR-203b-3p).
2 context sentences(design, population, supporting numbers)
Summary · context
Therefore, we performed a comprehensive analysis of microRNA serum levels in ovariectomized (OVX) and sham-operated (SHAM) rats over 12 weeks of antiresorptive or osteoanabolic treatment.
Summary · context
After 8 weeks, OVX rats were randomized to antiresorptive treatment with zoledronate (n = 11), osteoanabolic treatment with teriparatide (n = 11), or vehicle treatment (n = 10).
Report a problemFND-3359897507
08AnimalAnimal study (in vivo)Mechanism
In ovariectomized rats, teriparatide prevented significant serum miR-375-3p changes over time seen without treatment.
In plain wordsIn rats with ovaries removed, teriparatide prevented serum miR-375-3p changes seen without treatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeSerum miR-375-3p changes
Study
Sprague Dawley ratsn: not reported in source
Ovariectomized rats
Comparator
Vehicle-treated ovariectomized rats
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 12 weeksAs given in this study (Sprague Dawley rats).
Source sentences
Summary
Longitudinal analysis confirmed eight microRNAs with significant changes in serum over time that were prevented by teriparatide and zoledronate treatment (miR-34a-5p, miR-31-5p, miR-30d-3p, miR-378a-5p) or teriparatide treatment only (miR-375-3p, miR-183-5p, miR-203a-3p, miR-203b-3p).
2 context sentences(design, population, supporting numbers)
Summary · context
Therefore, we performed a comprehensive analysis of microRNA serum levels in ovariectomized (OVX) and sham-operated (SHAM) rats over 12 weeks of antiresorptive or osteoanabolic treatment.
Summary · context
After 8 weeks, OVX rats were randomized to antiresorptive treatment with zoledronate (n = 11), osteoanabolic treatment with teriparatide (n = 11), or vehicle treatment (n = 10).
Report a problemFND-3359897508
09AnimalAnimal study (in vivo)Mechanism
In ovariectomized rats, teriparatide prevented significant serum miR-183-5p changes over time seen without treatment.
In plain wordsIn rats with ovaries removed, teriparatide prevented serum miR-183-5p changes seen without treatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeSerum miR-183-5p changes
Study
Sprague Dawley ratsn: not reported in source
Ovariectomized rats
Comparator
Vehicle-treated ovariectomized rats
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 12 weeksAs given in this study (Sprague Dawley rats).
Source sentences
Summary
Longitudinal analysis confirmed eight microRNAs with significant changes in serum over time that were prevented by teriparatide and zoledronate treatment (miR-34a-5p, miR-31-5p, miR-30d-3p, miR-378a-5p) or teriparatide treatment only (miR-375-3p, miR-183-5p, miR-203a-3p, miR-203b-3p).
2 context sentences(design, population, supporting numbers)
Summary · context
Therefore, we performed a comprehensive analysis of microRNA serum levels in ovariectomized (OVX) and sham-operated (SHAM) rats over 12 weeks of antiresorptive or osteoanabolic treatment.
Summary · context
After 8 weeks, OVX rats were randomized to antiresorptive treatment with zoledronate (n = 11), osteoanabolic treatment with teriparatide (n = 11), or vehicle treatment (n = 10).
Report a problemFND-3359897509
10AnimalAnimal study (in vivo)Mechanism
In ovariectomized rats, teriparatide prevented significant serum miR-203a-3p changes over time seen without treatment.
In plain wordsIn rats with ovaries removed, teriparatide prevented serum miR-203a-3p changes seen without treatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeSerum miR-203a-3p changes
Study
Sprague Dawley ratsn: not reported in source
Ovariectomized rats
Comparator
Vehicle-treated ovariectomized rats
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 12 weeksAs given in this study (Sprague Dawley rats).
Source sentences
Summary
Longitudinal analysis confirmed eight microRNAs with significant changes in serum over time that were prevented by teriparatide and zoledronate treatment (miR-34a-5p, miR-31-5p, miR-30d-3p, miR-378a-5p) or teriparatide treatment only (miR-375-3p, miR-183-5p, miR-203a-3p, miR-203b-3p).
2 context sentences(design, population, supporting numbers)
Summary · context
Therefore, we performed a comprehensive analysis of microRNA serum levels in ovariectomized (OVX) and sham-operated (SHAM) rats over 12 weeks of antiresorptive or osteoanabolic treatment.
Summary · context
After 8 weeks, OVX rats were randomized to antiresorptive treatment with zoledronate (n = 11), osteoanabolic treatment with teriparatide (n = 11), or vehicle treatment (n = 10).
Report a problemFND-3359897510
11AnimalAnimal study (in vivo)Mechanism
In ovariectomized rats, teriparatide prevented significant serum miR-203b-3p changes over time seen without treatment.
In plain wordsIn rats with ovaries removed, teriparatide prevented serum miR-203b-3p changes seen without treatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeSerum miR-203b-3p changes
Study
Sprague Dawley ratsn: not reported in source
Ovariectomized rats
Comparator
Vehicle-treated ovariectomized rats
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 12 weeksAs given in this study (Sprague Dawley rats).
Source sentences
Summary
Longitudinal analysis confirmed eight microRNAs with significant changes in serum over time that were prevented by teriparatide and zoledronate treatment (miR-34a-5p, miR-31-5p, miR-30d-3p, miR-378a-5p) or teriparatide treatment only (miR-375-3p, miR-183-5p, miR-203a-3p, miR-203b-3p).
2 context sentences(design, population, supporting numbers)
Summary · context
Therefore, we performed a comprehensive analysis of microRNA serum levels in ovariectomized (OVX) and sham-operated (SHAM) rats over 12 weeks of antiresorptive or osteoanabolic treatment.
Summary · context
After 8 weeks, OVX rats were randomized to antiresorptive treatment with zoledronate (n = 11), osteoanabolic treatment with teriparatide (n = 11), or vehicle treatment (n = 10).
Report a problemFND-3359897511

Studies that did not test the peptide alone3

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

12AnimalNot a test of Teriparatide (PTH 1-34) aloneAnimal study (in vivo)Mechanism
In rats, analysis identified 11 circulating miRNAs significantly regulated after anti-osteoporotic treatment, without a separate teriparatide estimate.
In plain wordsIn rats, analysis identified 11 blood miRNAs that changed after osteoporosis treatment, without a separate teriparatide result.
Peptide
Teriparatide (PTH 1-34)
Outcome
Direction not reportedCirculating miRNA regulation after treatment
Study
Sprague Dawley ratsn: not reported in source
Ovariectomized and sham-operated rats
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
Differential expression analysis identified 11 circulating miRNAs that were significantly regulated after treatment.
2 context sentences(design, population, supporting numbers)
Summary · context
Therefore, we performed a comprehensive analysis of microRNA serum levels in ovariectomized (OVX) and sham-operated (SHAM) rats over 12 weeks of antiresorptive or osteoanabolic treatment.
Summary · context
After 8 weeks, OVX rats were randomized to antiresorptive treatment with zoledronate (n = 11), osteoanabolic treatment with teriparatide (n = 11), or vehicle treatment (n = 10).
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-3359897513
13AnimalNot a test of Teriparatide (PTH 1-34) aloneAnimal study (in vivo)Mechanism
In rats studied during anti-osteoporotic treatment, miR-203a-3p correlated negatively with vertebral and tibial trabecular bone volume fraction.
In plain wordsIn rats, higher miR-203a-3p levels were linked to lower spongy bone volume fractions in vertebrae and tibiae.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreasemiR-203a-3p correlation with trabecular bone volume fraction
Study
Sprague Dawley ratsn: not reported in source
Ovariectomized and sham-operated rats
Comparator
Vertebral and tibial trabecular bone volume fraction
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
Additional miRNAs were identified that showed significant correlations to bone microstructure or bone miRNA expression, including miR-203a-3p, which exhibited a significant negative correlation to vertebral and tibial trabecular bone volume fraction (%).
2 context sentences(design, population, supporting numbers)
Summary · context
Therefore, we performed a comprehensive analysis of microRNA serum levels in ovariectomized (OVX) and sham-operated (SHAM) rats over 12 weeks of antiresorptive or osteoanabolic treatment.
Summary · context
After 8 weeks, OVX rats were randomized to antiresorptive treatment with zoledronate (n = 11), osteoanabolic treatment with teriparatide (n = 11), or vehicle treatment (n = 10).
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-3359897514
14Computer modelNot a test of Teriparatide (PTH 1-34) aloneIn silicoMechanism
Gene target network analysis identified WNT and Notch as main pathways controlled by miRNAs studied during teriparatide and zoledronate treatment.
In plain wordsComputer analysis identified WNT and Notch as main pathways controlled by the studied miRNAs.
Peptide
Teriparatide (PTH 1-34)
Outcome
Not applicablemiRNA target pathways
Study
n: not reported in source
Gene target network analysis
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
Gene target network analysis identified WNT and Notch signaling as the main signaling pathways controlled by these miRNAs.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-3359897512

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.